Identification of DTYMK and CHEK1 as therapeutic targets in LKB1 mutant non-small cell lung cancer

被引：0
|
作者：
Liu, Yan [1 ]
Cowley, Glenn S. [2 ]
Cohoon, Travis J. [1 ]
Root, David E. [2 ]
Kwok-kin, Wong [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Broad Inst, Boston, MA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-LB-260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-260
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Molecular therapeutic targets in non-small cell lung cancer
    Sankar, Kamya
    Gadgeel, Shirish M.
    Qin, Angel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (08) : 647 - 661
  • [42] Novel Therapeutic Targets in Non-small Cell Lung Cancer
    Janku, Filip
    Garrido-Laguna, Ignacio
    Petruzelka, Lubos B.
    Stewart, David J.
    Kurzrock, Razelle
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1601 - 1612
  • [43] Novel therapeutic targets in non-small cell lung cancer
    Alamgeer, Muhammad
    Ganju, Vinod
    Watkins, D. Neil
    CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 394 - 401
  • [44] Human non-small cell lung cancer (NSCLC) cell lines with inactivated LKB1 and KRAS mutations are sensitive to MEK inhibition
    Mahoney, C.
    Choudhury, B.
    Davies, H.
    Bignell, G.
    Stratton, M.
    Futreal, A.
    EJC SUPPLEMENTS, 2008, 6 (09): : 32 - 33
  • [45] LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Tergemina-Clain, Gabrielle
    Faivre, Laura
    Pignon, Jean-Pierre
    Planchard, David
    Remon, Jordi
    Soria, Jean-Charles
    Lacroix, Ludovic
    Besse, Benjamin
    LUNG CANCER, 2017, 112 : 62 - 68
  • [46] LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
    Bonanno, Laura
    De Paoli, Angela
    Zulato, Elisabetta
    Esposito, Giovanni
    Calabrese, Fiorella
    Favaretto, Adolfo
    Santo, Antonio
    Del Conte, Alessandro
    Chilosi, Marco
    Oniga, Francesco
    Sozzi, Gabriella
    Moro, Massimo
    Ciccarese, Francesco
    Nardo, Giorgia
    Bertorelle, Roberta
    Candiotto, Cinzia
    De Salvo, Gian Luca
    Amadori, Alberto
    Conte, PierFranco
    Indraccolo, Stefano
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3316 - 3324
  • [47] LKB1 regulates BH3-mimetics vulnerability of KRAS mutant non-small cell lung cancer by alternating mitochondrial apoptotic protein interactions
    Li, Chendi
    Oh, Audris
    Nangia, Varuna
    Hata, Aaron N.
    CANCER RESEARCH, 2019, 79 (13)
  • [48] STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 108 - 113
  • [49] Heme sequestration modulates the tumor immune microenvironment in KRAS mutation/LKB1 inactivation non-small cell lung cancer
    Castro, Maria del Carmen Chacon
    Berisha, Eranda
    Salamat, Narges
    Zhang, Li
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer
    Ha Choi, Sun
    Do, Sook Kyung
    Lee, Shin Yup
    Choi, Jin Eun
    Kang, Hyo-Gyoung
    Hong, Mi Jeong
    Lee, Jang Hyuck
    Lee, Won Kee
    Jeong, Ji Yun
    Shin, Kyung Min
    Do, Young Woo
    Lee, Eung Bae
    Park, Ji Eun
    Lee, Yong Hoon
    Seo, Hyewon
    Yoo, Seung Soo
    Lee, Jaehee
    Cha, Seung Ick
    Kim, Chang Ho
    Park, Jae Yong
    THORACIC CANCER, 2022, 13 (23) : 3322 - 3330
12345